Suzhou Alphamab reported that its anti-PD-L1 antibody, KN035, was approved by the CFDA to begin clinical trials. Alphamab believes the candidate will be more effective and cause fewer side effects than the competition. Early in 2017, Alphamab formed a global partnership with 3DMed, a Shanghai precision drug company, to develop KN035 further. The FDA has also approved US clinical trials of the candidate.
